Retatrutide — the triple agonist generating buzz in 2026
DiscussionNews
249 views3 replies
If you're following GLP-1 research, retatrutide is the name to know. It's a triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously.
Why it matters:
- Phase 2 trial showed up to 24% body weight reduction at 48 weeks
- That's potentially better than tirzepatide (which hit ~22.5% in SURMOUNT)
- The glucagon receptor activation may help with fatty liver (big deal)
Current status:
- Eli Lilly is running Phase 3 trials
- Brand name will likely be something catchy
The interesting question: Does triple agonism actually translate to meaningfully better outcomes than dual (tirzepatide) or single (semaglutide) agonism? Or are we hitting a ceiling of diminishing returns?
What's everyone's read on this? Is triple agonism the future or are we overcomplicating things?
2/28/20260
3 Replies
Interesting that it says not yet available through research vendors.
I think the consensus is that Reta is a game changer with its ability to improve health multiple ways.
I just switched to Reta from Tirz and am really interested to see how it works out for me.
5/9/20261
@wooddhaven wrote:
Interesting that it says not yet available through research vendors.
I think the consensus is that Reta is a game changer with its ability to improve health multiple ways.
I just switched to Reta from Tirz and am really interested to see how it works out for me.
...
thanks, I'll edit that... incorrect information.. thanks for pointing it out, what's even more interesting their working on GLP-4's already.
5/9/20261